Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23086693 | 1.00 | KMT2A (0.39) | KMT2AITGB3ITGA2BCHRM1CHRM4 | |
| SCHEMBL23086683 | 1.00 | KMT2A (0.39) | KMT2AITGB3ITGA2BCHRM1CHRM4 | |
| SCHEMBL23086685 | 1.00 | KMT2A (0.39) | KMT2AITGB3ITGA2BCHRM1CHRM4 | |
| SCHEMBL21997783 | 0.83 | KMT2A (0.37) | KMT2AITGB3ITGA2BCHRM1HSD11B1 | |
| SCHEMBL22032262 | 0.82 | CHRM1 (0.55) | KMT2AITGB3ITGA2BCHRM1CHRM4 | |
| SCHEMBL26636154 | 0.82 | CHRM1 (0.55) | KMT2AITGB3ITGA2BCHRM1CHRM4 | |
| SCHEMBL24208582 | 0.82 | CHRM1 (0.55) | KMT2AITGB3ITGA2BCHRM1CHRM4 | |
| SCHEMBL26636161 | 0.82 | CHRM1 (0.55) | KMT2AITGB3ITGA2BCHRM1CHRM4 | |
| SCHEMBL8882240 | 0.79 | HTR2C (0.47) | CHRM1CHRM4CHRM5GPR119 | |
| SCHEMBL8882236 | 0.79 | HTR2C (0.47) | CHRM1CHRM4CHRM5GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3891143-B1 | QUINOLINONE AND BENZOXAZINE DERIVATIVES AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2024-01-31 | — | — | EP | disclosed |
| US-20220017504-A1 | QUINOLINONE AND BENZOXAZINE DERIVATIVES AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-01-20 | — | — | US | disclosed |
| EP-3891143-A1 | QUINOLINONE AND BENZOXAZINE DERIVATIVES AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020115506-A1 | QUINOLINONE AND BENZOXAZINE DERIVATIVES AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017504-A1 | QUINOLINONE AND BENZOXAZINE DERIVATIVES AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM4, CHRM2 | KMT2A 2013/4885ITGB3 2863/4885ITGA2B 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.